Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
The Neurohospitalist|April 13, 2017
Neurosarcoidosis Presenting With Recurrent Strokes: A Case Report and Literature ReviewNaheed Raza, Karisa C SchreckOncology (Williston Park, N.Y.)|November 27, 2018
Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous SystemKarisa C Schreck, Stuart A GrossmanCancers|August 31, 2019
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain TumorsKarisa C Schreck, Stuart A Grossman, Christine A PratilasExpert Review of Anticancer Therapy|February 7, 2022
High-grade glioma therapy: adding flexibility in trial design to improve patient outcomesXiaobu Ye, Karisa C Schreck, Byram H Ozer, et al.Neuro-Oncology Advances|November 25, 2020
Combination MEK and mTOR inhibitor therapy is active in models of glioblastomaKarisa C Schreck, Amy N Allen, Jiawan Wang, et al.Neuro-Oncology Practice|August 9, 2020
RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse eventsKarisa C Schreck, Mallika P Patel, Jan Wemmer, et al.Cancer Research|January 20, 2011
Notch3 activation promotes invasive glioma formation in a tissue site-specific mannerTarran J Pierfelice, Karisa C Schreck, Louis Dang, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2018
Concurrent BRAF/MEK Inhibitors in <i>BRAF</i> V600-Mutant High-Grade Primary Brain TumorsKarisa C Schreck, Andrew Guajardo, Doris D M Lin, et al.Molecular Cancer Therapeutics|May 7, 2024
MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient GlioblastomaMaria Ioannou, Kriti Lalwani, Abiola A Ayanlaja, et al.Neuro-Oncology Advances|March 19, 2026
Durable disease control in a radiation-induced high-grade glioma harboring <i>NF1</i> and <i>PTPN11</i> co-mutationsMohamed Sherief, Maria Fatteh, Jaime Wehr, et al.Pageof 6